首页> 外文期刊>Influenza and other respiratory viruses. >Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014–2015 influenza season in Alberta, Canada
【24h】

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014–2015 influenza season in Alberta, Canada

机译:2014-2015年加拿大艾伯塔省流感季节从免疫受损患者中分离出的甲型流感病毒(H3N2)的Oseltamivir耐药性

获取原文
           

摘要

This manuscript describes the identification of an oseltamivir-resistant influenza A (H3N2) virus in a respiratory specimen collected from an immunocompromised patient in Alberta, Canada, during the 2014–2015 influenza season. Following treatment with oseltamivir, neuraminidase (NA) gene sequencing indicated the presence of an R292K mutation. Phenotypic susceptibility testing by the NA-Star assay indicated a highly reduced inhibition by oseltamivir and normal inhibition by zanamivir. The use of zanamivir following identification of the oseltamivir-resistant strain, combined with a partial immune reconstitution, was followed by a suggested decrease in the nasopharyngeal viral load in the nasopharynx and clinical improvement of the patient.
机译:该手稿描述了在2014-2015年流感季节期间从加拿大艾伯塔省一名免疫受损患者收集的呼吸道标本中鉴定出耐奥司他韦的甲型H3N2流感病毒。用奥司他韦治疗后,神经氨酸酶(NA)基因测序表明存在R292K突变。通过NA-Star试验进行的表型药敏试验表明,奥司他韦的抑制作用大大降低,而扎那米韦的抑制作用正常。在鉴定出耐奥司他韦的菌株后结合使用扎那米韦,并进行部分免疫重建,然后建议减少鼻咽中的鼻咽病毒载量并改善患者的临床状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号